Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180
Author(s) -
Steven P. Treon,
Leukothea Ioakimidis,
Jacob D. Soumerai,
Christopher J. Patterson,
Patricia Sheehy,
Marybeth Nelson,
Michael A. Willen,
Jeffrey Matous,
John Q. A. Mattern,
Jakow G. Diener,
George P. Keogh,
Thomas J. Myers,
Andy Boral,
Ann Birner,
Dixie Esseltine,
Irene M. Ghobrial
Publication year - 2009
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2008.20.4677
Subject(s) - medicine , bortezomib , rituximab , macroglobulinemia , waldenstrom macroglobulinemia , dexamethasone , gastroenterology , surgery , progressive disease , peripheral neuropathy , multiple myeloma , chemotherapy , lymphoma , endocrinology , diabetes mellitus
We examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in patients with symptomatic, untreated Waldenström macroglobulinemia (WM).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom